| Year |
Citation |
Score |
| 2019 |
Kaur S, Schwartz AL, Jordan DG, Soto-Pantoja DR, Kuo B, Elkahloun AG, Mathews Griner L, Thomas CJ, Ferrer M, Thomas A, Tang SW, Rajapakse VN, Pommier Y, Roberts DD. Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors. Frontiers in Oncology. 9: 994. PMID 31632920 DOI: 10.3389/Fonc.2019.00994 |
0.375 |
|
| 2019 |
Schwartz AL, Nath PR, Allgauer M, Lessey-Morillon EC, Sipes JM, Ridnour LA, Morillon Ii YM, Yu Z, Restifo NP, Roberts DD. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. Cancer Immunology, Immunotherapy : Cii. PMID 31628526 DOI: 10.1007/S00262-019-02397-7 |
0.37 |
|
| 2019 |
Nath PR, Pal-Nath D, Mandal A, Cam MC, Schwartz AL, Roberts DD. Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment. Cancer Immunology Research. PMID 31362997 DOI: 10.1158/2326-6066.Cir-18-0367 |
0.358 |
|
| 2018 |
Feliz-Mosquea YR, Christensen AA, Wilson AS, Westwood B, Varagic J, Meléndez GC, Schwartz AL, Chen QR, Mathews Griner L, Guha R, Thomas CJ, Ferrer M, Merino MJ, Cook KL, Roberts DD, et al. Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy. Breast Cancer Research and Treatment. PMID 30056566 DOI: 10.1007/S10549-018-4884-X |
0.361 |
|
| 2017 |
Schwartz AL, Dickerson E, Dagia N, Malgor R, McCall KD. TLR signaling inhibitor, phenylmethimazole, in combination with tamoxifen inhibits human breast cancer cell viability and migration. Oncotarget. 8: 113295-113302. PMID 29371911 DOI: 10.18632/Oncotarget.10358 |
0.321 |
|
| 2017 |
Schwartz AL, Nath P, Lessey-Morillon E, Ridnour L, Allgaeuer M, Roberts D. CTLA4 and CD47 combinational therapy to extend survival in melanoma. Journal of Clinical Oncology. 35: e21025-e21025. DOI: 10.1200/Jco.2017.35.15_Suppl.E21025 |
0.359 |
|
| 2016 |
Schwartz AL, Kaur S, Tang S, Pommier Y, Roberts DD. Abstract 3054: CD47 signaling regulates a DNA damage response pathway by suppressing the expression of Schlafen-11 (SLFN11) Cancer Research. 76: 3054-3054. DOI: 10.1158/1538-7445.Am2016-3054 |
0.367 |
|
| 2015 |
Miller TW, Soto-Pantoja DR, Schwartz AL, Sipes JM, DeGraff WG, Ridnour LA, Wink DA, Roberts DD. CD47 Globally Regulates Metabolic Pathways that Control Resistance to Ionizing Radiation. The Journal of Biological Chemistry. PMID 26311851 DOI: 10.1074/Jbc.M115.665752 |
0.339 |
|
| 2015 |
Kaur S, Schwartz AL, Miller TW, Roberts DD. CD47-dependent regulation of H₂S biosynthesis and signaling in T cells. Methods in Enzymology. 555: 145-68. PMID 25747479 DOI: 10.1016/Bs.Mie.2014.11.023 |
0.336 |
|
| 2013 |
Schwartz AL, Custis JT, Harmon JF, Powers BE, Chubb LS, LaRue SM, Ehrhart NP, Ryan SD. Orthotopic model of canine osteosarcoma in athymic rats for evaluation of stereotactic radiotherapy. American Journal of Veterinary Research. 74: 452-8. PMID 23438123 DOI: 10.2460/Ajvr.74.3.452 |
0.477 |
|
| 2012 |
Benavides U, Gonzalez-Murguiondo M, Harii N, Lewis CJ, Schwartz AL, Giuliani C, Napolitano G, Dagia NM, Malgor R, McCall KD, Kohn LD. Phenylmethimazole inhibits production of proinflammatory mediators and is protective in an experimental model of endotoxic shock*. Critical Care Medicine. 40: 886-94. PMID 22020240 DOI: 10.1097/Ccm.0B013E318236Ef8B |
0.303 |
|
| 2009 |
Schwartz AL, Malgor R, Dickerson E, Weeraratna AT, Slominski A, Wortsman J, Harii N, Kohn AD, Moon RT, Schwartz FL, Goetz DJ, Kohn LD, McCall KD. Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4114-22. PMID 19470740 DOI: 10.1158/1078-0432.Ccr-09-0005 |
0.335 |
|
| Show low-probability matches. |